GamaMab's Pockets Replenished: Funds For Gynecological Cancer Trials
This article was originally published in Scrip
Executive Summary
French biotech GamaMabs Pharma has raised €15m in a series B financing round, led by new investor BioDiscovery 4, with hopes to use the money to fund Phase I and Phase II clinical trials of GamaMabs' lead product GM102 (formerly known as 3C23K) for gynecological cancers.